VivoSeq
Immunology

Lupus Erythematosus, Systemic

6

Pipeline Programs↗

6

Active Trials↗

4

Companies Involved↗

Lupus Erythematosus, Systemic is an early-stage landscape with 6 programs across 4 companies. The most active players are Roche, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

19/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1J

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule343%
Monoclonal antibody229%
Cell therapy229%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting4 · 57%
Not yet recruiting2 · 29%
Completed1 · 14%

Clinical Trials

Trial Activity

7 trials

A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)
Recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT06897930·150 enrolled
DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07330245·218 enrolled
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·NCT07015983·89 enrolled
Effectiveness of Subcutaneous Anifrolumab in Systemic Lupus Erythematodes - A Non-interventional, Prospective, Multicenter Study on Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07424261·125 enrolled
An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Not yet recruiting·Roche logoRoche·Phase 1·NCT07629583·46 enrolled
CD19-targeted Lymphocyte Engineering Validation for the trEatment of Refractory Systemic Lupus Erythematosus
Not yet recruiting·UUniversity of Sao Paulo·Preclinical·NCT07659704·16 enrolled
Using the Cholinergic Anit-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
Completed·NNorthwell Health·Preclinical·NCT02822989·19 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)